Gene editing can be used to overcome allo-recognition, which otherwise limits allogeneic T cell therapies. Initial proof-ofconcept applications have included generation of such "universal" T cells expressing chimeric antigen receptors (CARs) against CD19 target antigens combined with transient expression of DNA-targeting nucleases to disrupt the T cell receptor alpha constant chain (TRAC). Although relatively efficient, transgene expression and editing effects were unlinked, yields variable, and resulting T cell populations heterogeneous, complicating dosing strategies. We describe a self-inactivating lentiviral "terminal" vector platform coupling CAR expression with CRISPR/Cas9 effects through incorporation of an sgRNA element into the DU3 3 0 long terminal repeat (LTR). Following reverse transcription and duplication of the hybrid DU3-sgRNA, delivery of Cas9 mRNA resulted in targeted TRAC locus cleavage and allowed the enrichment of highly homogeneous (>96%) CAR + (>99%) TCR À populations by automated magnetic separation. Molecular analyses, including NGS, WGS, and Digenome-seq, verified on-target specificity with no evidence of predicted off-target events. Robust antileukemic effects were demonstrated in humanized immunodeficient mice and were sustained longer than by conventional CAR + TCR + T cells. Terminal-TRAC (TT) CAR T cells offer the possibility of a pre-manufactured, non-HLA-matched CAR cell therapy and will be evaluated in phase 1 trials against B cell malignancies shortly.
INTRODUCTION
T cells engineered to express recombinant antigen-specific receptors or chimeric antigen receptors are in multi-phase trials, with some approaches yielding compelling remission effects against refractory leukemia.
1 The majority of subjects treated to date have provided and received autologous T cells, but this approach may not be best suited for widespread cost-effective delivery of cellular therapy. Gene editing offers the prospect of addressing human leukocyte (HLA) À barriers and the development of universal T cell therapies.
2,3
Recently, T cells modified using transcription activator-like effector nucleases (TALENs) and expressing chimeric antigen receptor (CAR) against CD19 have been used to treat refractory relapsed B cell acute lymphoblastic leukemia (B-ALL) in infants. 4 These "off the shelf" cells were derived from a non-HLA-matched donor and were disrupted for CD52 expression to evade the depletion effects of alemtuzumab and were simultaneously modified at the T cell receptor (TCR) alpha chain constant (TRAC) region and depleted of T cells expressing TCRab to reduce the risk of graft versus host disease (GVHD). 5 Clinical trials are underway to assess the strategy further in children and adults and key aspects determining dosing schedules related to carriage of residual TCRab T cells and the proportion of cells expressing CAR19. The former comprise less than 1% of the total cell inoculum after TCRab magnetic bead depletion but constitute a risk for GVHD and are strictly capped to below 5 Â 10 4 T cells/kg. 6 This, in turn, limits the total cell dose, and because only a proportion of cells express CAR19 as a result of batch-to-batch variation in lentiviral transduction efficiency, the total cell dosing regimen differs between batches. Similar issues arise for other gene editing platforms relying on segregated DNA nuclease delivery, whether by non-integrating viral delivery of zinc-finger nucleases 3 or megaTALs combined with non-viral delivery.
7
We designed a self-inactivating (SIN) lentiviral platform that coupled transgene expression with CRISPR editing effects for efficient and homogeneous T cell modification ( Figure 1A ) and demonstrated that this system is scalable and can be incorporated into a largely automated manufacturing process. CRISPR-mediated effects in CAR19-modified T cells have been reported previously. For example, Ren et al. 8, 9 used CRISPR RNA electroporation to disrupt endogenous TCR and b 2 -microglobulin (B2M) genes for disruption of major histocompatibility complex (MHC) class I in T cells transduced with a lentiviral CAR vector, but editing and transgene effects were unlinked. Other lentiviral configurations have incorporated both CRISPR guide sequences and Cas9 expression cassettes that become integrated into the target cell genome as a constituent of proviral vector DNA.
10 Although suitable for pre-clinical studies, constitutive expression of Cas9 would be problematic in human trials, not the least because of its bacterial origin and likely immunogenicity. To overcome this issue, we delivered capped, polyadenylated, uridine-modified Cas9 mRNA by electroporation to T cells that had been transduced with our "terminal-CRISPR" lentiviral configuration. Here, CAR19 was expressed under the control of an internal human promoter, and CRISPR guide sequences and associated H1/U6 promoters were incorporated into the U3 region of the 3 0 long terminal repeat (LTR) sequence of the vector. Previous vector configurations using these flanking regions have included a g-retroviral vector for expression of cDNA cassettes 11 and a lentiviral system encoding short hairpin RNA interference elements.
12 Modification of the LTR can impair retroviral titers but has a number of advantages, including avoiding interference with internal promoters 13 and duplication of sequences cited in the U3 locus following reverse transcription. Here we adopt and refine this approach for CRISPR delivery, anticipating guide duplication and incorporation into the 5 0 LTR during reverse transcription and vectorized linkage of guide effects with transgene expression. We demonstrate compliant scalability and the potential of the platform for the generation of "universal" human T cells on a clinical scale. Potent anti-leukemic effects of TCR-depleted CAR19 T cells were demonstrated in a human:-murine chimeric tumor model. Multi-modal analysis confirmed highly efficient "on-target" modifications with no predicted or unpredicted "off-target" events recorded.
RESULTS

Design and Construction of Lentiviral Terminal-TRAC Guide RNA Vectors
Incorporation of a Pol III promoter and single guide RNA (sgRNA) sequence into the 3 0 LTR of a U3-deleted third-generation lentiviral vector generated a self-duplicating CRISPR expression cassette (Figure 1B) . A region immediately proximal to 3 0 repeat (R) regions was selected to preserve reverse transcription-mediated duplication to the 5 0 LTR, resulting in a proviral form with both 5 0 and 3 0 flanking terminal CRISPR elements ( Figure 1C ). For targeting of endogenous TCR expression, a sgRNA sequence targeting the TRAC locus (specificity score 94/100 14 ) was placed under the control of the human Pol III promoter, U6, followed by a sgRNA sequence specific for S. pyogenes Cas9, which was delivered separately as mRNA by electroporation ( Figure 1D ). The lentiviral vector encoded a chimeric antigen receptor (CAR19) under the control of an internal human phosphoglycerate kinase (PGK) promoter. The concentrated vector titer of this "Terminal-TRAC" (TT) configuration (TT-hPGK-CAR19) was
